Moderna is trading 4.1% up today at $57.41, rebounding from recent post-earnings volatility as the broader biotech sector rallies.
- Investors are positioning ahead of the August 5 FDA decision on the company's mRNA flu vaccine and other 2026 pipeline catalysts.
- Supportive risk-on sentiment across major U.S. indices is providing additional tailwinds for the stock.